|
ATP5B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.8748000030786E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.13210000041164E-07 |
| Normal-vs-Stage2 |
2.969400E-01 |
| Normal-vs-Stage3 |
3.50619977496081E-10 |
| Normal-vs-Stage4 |
5.11868325503428E-12 |
| Stage1-vs-Stage2 |
5.464300E-03 |
| Stage1-vs-Stage3 |
6.422000E-02 |
| Stage1-vs-Stage4 |
2.135700E-03 |
| Stage2-vs-Stage3 |
9.212100E-04 |
| Stage2-vs-Stage4 |
2.170600E-04 |
| Stage3-vs-Stage4 |
2.312400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.08769709589774E-11 |
| Normal-vs-AfricanAmerican |
1.00690000004455E-06 |
| Normal-vs-Asian |
2.10049999999073E-05 |
| Caucasian-vs-AfricanAmerican |
7.845200E-01 |
| Caucasian-vs-Asian |
9.460800E-01 |
| AfricanAmerican-vs-Asian |
8.906200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.27140000000193E-05 |
| Normal-vs-Female |
1.23279999986181E-07 |
| Male-vs-Female |
8.885800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.22249999976599E-07 |
| Normal-vs-Age(41-60Yrs) |
3.25950000323871E-08 |
| Normal-vs-Age(61-80Yrs) |
9.222300E-02 |
| Normal-vs-Age(81-100Yrs) |
1.972670E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.789200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.074980E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.100800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.473800E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.662400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.101500E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.758300E-03 |
| Classical-VS-Follicular |
1.68325999999608E-05 |
| Classical-VS-Other |
7.431800E-01 |
| Classical-VS-Normal |
1.31972210937192E-12 |
| Tall-VS-Follicular |
9.52669999554345E-08 |
| Tall-VS-Other |
6.726000E-01 |
| Tall-VS-Normal |
1.4432899320127E-15 |
| Follicular-VS-Other |
8.777700E-03 |
| Follicular-VS-Normal |
3.348000E-01 |
| Other-VS-Normal |
6.364600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.768560E-04 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
5.71720004671761E-09 |
|
|
